AbCellera Biologics Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was USD 38.03 million compared to USD 485.42 million a year ago. Net loss was USD 146.4 million compared to net income of USD 158.52 million a year ago.

Basic loss per share from continuing operations was USD 0.51 compared to basic earnings per share from continuing operations of USD 0.56 a year ago. Diluted loss per share from continuing operations was USD 0.51 compared to diluted earnings per share from continuing operations of USD 0.5 a year ago.